NCT06896916 - Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

August 7, 2025

Primary Completion Date

March 31, 2036

Study Completion Date

March 31, 2036

Conditions

Multiple Myeloma

Interventions

DRUG

Etentamig

Intravenous (IV) Infusion

DRUG

Iberdomide

Oral Capsule

Trial Locations (14)

2148

RECRUITING

Blacktown Hospital /ID# 265983, Blacktown

2500

RECRUITING

Wollongong Hospital /ID# 265625, Wollongong

3084

RECRUITING

Austin Hospital /ID# 265984, Melbourne

31059

RECRUITING

IUCT Oncopole /ID# 266391, Toulouse

37000

RECRUITING

Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau /ID# 267694, Tours

63110

RECRUITING

Washington University /ID# 266972, St Louis

80218

RECRUITING

Colorado Blood Cancer Institute /ID# 273751, Denver

08901

RECRUITING

Rutgers Cancer Institute of New Jersey /ID# 266833, New Brunswick

860-8556

RECRUITING

Kumamoto University Hospital /ID# 270530, Kumamoto

321-0293

RECRUITING

Dokkyo Medical University Hospital /ID# 271648, Mibu

113-8603

RECRUITING

Nippon Medical School Hospital /ID# 270254, Bunkyo-ku

135-8550

RECRUITING

The Cancer Institute Hospital Of JFCR /ID# 268342, Koto-ku

3584 CX

RECRUITING

Universitair Medisch Centrum Utrecht /ID# 267660, Utrecht

0450

RECRUITING

Oslo Universitetssykehus Ulleval /ID# 275433, Oslo